vs
Side-by-side financial comparison of NeuroPace Inc (NPCE) and VersaBank (VBNK). Click either name above to swap in a different company.
VersaBank is the larger business by last-quarter revenue ($26.7M vs $26.6M, roughly 1.0× NeuroPace Inc). VersaBank runs the higher net margin — 30.3% vs -10.3%, a 40.6% gap on every dollar of revenue. On growth, VersaBank posted the faster year-over-year revenue change (31.2% vs 23.9%). Over the past eight quarters, NeuroPace Inc's revenue compounded faster (21.1% CAGR vs 16.6%).
NeuroPace Inc is a medical technology company focused on developing and commercializing innovative implantable neurostimulation systems to treat neurological disorders, primarily drug-resistant epilepsy. Its core RNS System delivers personalized responsive stimulation to reduce seizure frequency, serving patients across North America and select global markets via partnerships with healthcare providers.
VersaBank is a Canada-based digital-first financial institution offering commercial lending, high-interest deposit accounts and customized financial services for SMEs, retail clients and institutional partners across North America. It operates no physical branches, using secure digital infrastructure to deliver efficient, cost-effective banking experiences.
NPCE vs VBNK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $26.6M | $26.7M |
| Net Profit | $-2.7M | $8.1M |
| Gross Margin | 77.4% | — |
| Operating Margin | -6.6% | — |
| Net Margin | -10.3% | 30.3% |
| Revenue YoY | 23.9% | 31.2% |
| Net Profit YoY | 48.0% | 35.9% |
| EPS (diluted) | $-0.08 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.7M | ||
| Q4 25 | $26.6M | — | ||
| Q3 25 | $27.4M | $23.1M | ||
| Q2 25 | $23.5M | $22.0M | ||
| Q1 25 | $22.5M | $20.3M | ||
| Q4 24 | $21.5M | — | ||
| Q3 24 | $21.1M | $19.7M | ||
| Q2 24 | $19.3M | $20.8M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $-2.7M | — | ||
| Q3 25 | $-3.5M | $4.8M | ||
| Q2 25 | $-8.7M | $6.2M | ||
| Q1 25 | $-6.6M | $5.9M | ||
| Q4 24 | $-5.3M | — | ||
| Q3 24 | $-5.5M | $7.1M | ||
| Q2 24 | $-7.5M | $8.6M |
| Q1 26 | — | — | ||
| Q4 25 | 77.4% | — | ||
| Q3 25 | 77.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 77.0% | — | ||
| Q4 24 | 75.4% | — | ||
| Q3 24 | 73.2% | — | ||
| Q2 24 | 73.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | -6.6% | — | ||
| Q3 25 | -9.5% | — | ||
| Q2 25 | -29.0% | — | ||
| Q1 25 | -22.9% | — | ||
| Q4 24 | -17.0% | — | ||
| Q3 24 | -20.1% | — | ||
| Q2 24 | -32.4% | — |
| Q1 26 | — | 30.3% | ||
| Q4 25 | -10.3% | — | ||
| Q3 25 | -12.8% | 20.8% | ||
| Q2 25 | -36.8% | 28.3% | ||
| Q1 25 | -29.3% | 29.3% | ||
| Q4 24 | -24.5% | — | ||
| Q3 24 | -25.9% | 35.9% | ||
| Q2 24 | -39.0% | 41.5% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.26 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $-0.19 | — | ||
| Q2 24 | $-0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $61.1M | $458.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $19.0M | $396.4M |
| Total Assets | $105.6M | $4.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $458.4M | ||
| Q4 25 | $61.1M | — | ||
| Q3 25 | $60.0M | $336.0M | ||
| Q2 25 | $62.1M | $248.3M | ||
| Q1 25 | $66.3M | $282.3M | ||
| Q4 24 | $52.8M | — | ||
| Q3 24 | $56.8M | $181.0M | ||
| Q2 24 | $55.5M | $145.1M |
| Q1 26 | — | $396.4M | ||
| Q4 25 | $19.0M | — | ||
| Q3 25 | $18.5M | $385.5M | ||
| Q2 25 | $19.4M | $385.7M | ||
| Q1 25 | $24.3M | $380.5M | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $9.8M | $298.6M | ||
| Q2 24 | $9.9M | $292.1M |
| Q1 26 | — | $4.5B | ||
| Q4 25 | $105.6M | — | ||
| Q3 25 | $107.3M | $4.0B | ||
| Q2 25 | $106.1M | $3.7B | ||
| Q1 25 | $110.2M | $3.6B | ||
| Q4 24 | $94.6M | — | ||
| Q3 24 | $96.3M | $3.3B | ||
| Q2 24 | $94.4M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $506.0K | $40.6M |
| Free Cash FlowOCF − Capex | $409.0K | — |
| FCF MarginFCF / Revenue | 1.5% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | 5.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-11.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.6M | ||
| Q4 25 | $506.0K | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-7.5M | $-65.0M | ||
| Q4 24 | $-4.8M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-3.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $409.0K | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-7.5M | — | ||
| Q4 24 | $-4.8M | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-4.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | — | ||
| Q3 25 | -7.2% | — | ||
| Q2 25 | -9.6% | — | ||
| Q1 25 | -33.4% | — | ||
| Q4 24 | -22.5% | — | ||
| Q3 24 | -8.7% | — | ||
| Q2 24 | -20.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.3% | — |
| Q1 26 | — | 5.03× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -10.94× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
